RankAlpha logo
Back to Rankings

ANRO

Alto NeuroscienceB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bullish view is that the March financing and roughly $275 million pro forma cash position buy enough runway to let ALTO-207, ALTO-300, and ALTO-100 reset sentiment after the ALTO-101 setback, with ALTO-207 now the lead value driver and potentially the clearest rerating path [#8-K-2026-04-01] [#10-K-2026-03-16].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +12.2.
What can break
ALTO-101 failed to hit statistical significance on primary EEG and cognitive endpoints, reducing pipeline breadth.
Momentum
61
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $32.32
Why
Momentum61 · Δ7d -12.4
Value41 · Δ7d +0.1
Sentiment83 · Δ7d +12.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
61
34% active weight
Current posture
7d trendSoftening
Δ7d
-12.4
Δ21d
-30.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
83
33% active weight
Current posture
7d trendImproving
Δ7d
+12.2
Δ21d
+33.3
Why this grade

Composite grade B. Momentum 61.0 / Value 41.1 / Sentiment 83.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$694.86M
Beta
-
Shares Out
31.07M
P/E (TTM) · Derived
-8.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.22
Rev YoY
-
EPS YoY
+16.0%
Gross Margin
-
Op Margin
-
Net Debt
-$156.67M
Current Ratio
15.42
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology